other material
confidence high
sentiment positive
materiality 0.75
Rezolute reports positive interim Phase 3 upLIFT data: 6 of 8 patients met primary endpoint
Rezolute, Inc.
- 8 patients enrolled (50% of planned 16); 6 responders with ≥50% reduction in IV glucose, all 6 achieved complete discontinuation.
- One patient withdrew due to cancer progression (Stage 4 colon cancer) counted as non-responder; one patient recently enrolled and dosing.
- No drug-related adverse events; all completing pivotal phase entered open-label extension, cumulative treatment up to 6 months.
- Topline results for fully enrolled study expected in second half of 2026.
- Data supports ersodetug as potential universal treatment for refractory hypoglycemia from congenital and acquired hyperinsulinism.